TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $28.
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $28.